United States — Food and Drug Administration & Amgen

United States — Food and Drug Administration: The United States — Food and Drug Administration characterized the medication recall as Class II and is overseeing the recall process initiated by Amgen, ensuring public safety and regulatory compliance.

Amgen: Amgen voluntarily recalled nearly one million bottles of its Corlanor and Sensipar tablets due to the presence of a foreign substance, impacting its product distribution and potentially its reputation, though the health risk is deemed low.

United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.

Amgen: Competitor with injectable PCSK9 inhibitor Repatha; faces potential market share loss to oral alternative.

United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.

Amgen: Amgen is a key player in the antibody therapeutics market, benefiting from the projected market growth.

United States — Food and Drug Administration: The United States — Food and Drug Administration>>> (FDA) is the regulatory body reviewing Alvogen's resubmitted applications for AVT05 and AVT06. Their decision will determine the market entry of these biosimilars in the United States>>>.

Amgen: Amgen>>> owns the trademarks for Prolia and Xgeva, the reference products for Alvogen>>>'s AVT03 biosimilar. While not directly related to the current resubmissions, it highlights the competitive landscape Alvogen>>> operates in.